Intestinal Research

Original Article

IBD

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis: Vandana Midha, Ramit Mahajan, Varun Mehta, Vikram Narang, Arshdeep Singh, Kirandeep Kaur, Ajit Sood; Intest Res 2018;16(1):83-89. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.83

<b>Background/Aims</b><br/>

Data on the efficacy and safety of the adalimumab biosimilar Exemptia are limited.

Methods

Patients with moderate-to-severe active steroid-refractory ulcerative colitis (UC) treated at Dayanand Medical College and Hospital, India were offered cyclosporine A, biologicals or biosimilars, or surgery. A retrospective analysis was conducted on patients who were treated with the adalimumab biosimilar, Exemptia. These patients were administered an induction dosing schedule of 160 mg Exemptia at week 0, 80 mg at week 2, and then 40 mg every other week from week 4 to 8. The clinical response and remission were assessed at week 8 using Mayo score.

Results

A total of 29 patients (62.1% male; mean age, 34.9 ± 9.7 years) with moderate-to-severe steroid-refractory active UC (mean disease duration, 6.3±5.1 years; pancolitis in 9 patients [31.1%]; left-sided colitis in 20 patients [68.9%]) were treated with the Exemptia induction dosing schedule. The mean Mayo score at presentation was 8.2±1.4. At week 8, clinical response was observed in 7 patients (24.1%), whereas clinical remission was observed only in 1 patient (3.5%). Among the non-responders (n=21), 4 patients required colectomy, 1 died, 1 was lost to follow-up, 10 were offered fecal microbiota transplant, 3 were administered infliximab, and 2 patients were administered cyclosporine and tacrolimus, respectively. Four patients (13.8%) developed extrapulmonary tuberculosis.

Conclusions

The adalimumab biosimilar Exemptia has limited efficacy for the attainment of clinical response and remission in moderate-to-severe steroid-refractory UC, with a significant risk of acquisition or reactivation of tuberculosis in developing countries such as India.

Citations

Citations to this article as recorded by

Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, Giovanni Aragona, Maria Antonia Bianco, Raffaele Colucci, Antonio Cuomo, Nicola Della Valle, Antonio Ferronato, Giacomo Forti, Federica Gaiani, GianMarco Giorgetti, Maria Giovanna Graziani, Katia Lofano
Inflammatory Bowel Diseases.2023; 29(3): 376. CrossRef
Crohn’s Disease Among the Poorest Billion: Burden of Crohn’s Disease in Low- and Lower-Middle-Income Countries
Ruma Rajbhandari, Samantha Blakemore, Neil Gupta, Sara Mannan, Klejda Nikolli, Alison Yih, Laura Drown, Gene Bukhman
Digestive Diseases and Sciences.2023; 68(4): 1226. CrossRef
The Long-Term Effects of Short-Period Adalimumab Biosimilar Usage in Ankylosing Spondylitis
Arvind Chopra, Nagnath Khadke, Manjit Saluja, Toktam Kianifard, Anuradha Venugopalan, Mihir Gharia
Cureus.2023;[Epub] CrossRef
Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti‐TNF therapy in tuberculosis endemic region
Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Pabitra Sahu, Sandeep Goyal, Deepak Madhu, Saransh Jain, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Singh, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Mani Kalaivani, Raju Sharma, Prasenjit
Alimentary Pharmacology & Therapeutics.2022; 55(11): 1431. CrossRef
Challenges for biosimilars: focus on rheumatoid arthritis
Muhammad Safwan Akram, Neelam Pery, Lucy Butler, Muhammad Imtiaz Shafiq, Nayab Batool, Muhammad Fayyaz ur Rehman, Luke G. Grahame-Dunn, Ali K. Yetisen
Critical Reviews in Biotechnology.2021; 41(1): 121. CrossRef
Evaluation of adalimumab biosimilar in treatment of psoriatic arthritis with concomitant moderate to severe chronic plaque psoriasis: An open-labeled, prospective, pilot case series
Sujay Khandpur, Prateek Sondhi, Neha Taneja, Preeti Sharma, Dayasagar Das, Alpana Sharma, Vishnubatla Sreenivas
Journal of the American Academy of Dermatology.2020; 83(1): 248. CrossRef
Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis
Saurabh Kedia, Venigalla Pratap Mouli, Nagesh Kamat, Jeeva Sankar, Ashwin Ananthakrishnan, Govind Makharia, Vineet Ahuja
American Journal of Gastroenterology.2020; 115(3): 340. CrossRef
Biosimilars in inflammatory bowel disease
Saurabh Talathi, Kondal R. Kyanam Kabir Baig
Journal of Digestive Diseases.2020; 21(11): 610. CrossRef
Rapid attainment of target trough concentrations of tacrolimus for early improvement of clinical symptoms in patients with ulcerative colitis
Yuto Yamada, Yuta Ohno, Takashi Niwa, Hiroko Kato‐Hayashi, Hideki Hayashi, Takashi Ibuka, Hiroshi Araki, Tadashi Sugiyama, Masahito Shimizu, Akio Suzuki
Journal of Clinical Pharmacy and Therapeutics.2019; 44(3): 409. CrossRef
Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study
Nagesh Kamat, Saurabh Kedia, Uday C. Ghoshal, Abhimanyu Nehra, Govind Makharia, Ajit Sood, Vandana Midha, Varun Gupta, Gourdas Choudhuri, Vineet Ahuja
Indian Journal of Gastroenterology.2019; 38(1): 44. CrossRef
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
Marjorie Argollo, Gionata Fiorino, Daniela Gilardi, Federica Furfaro, Giulia Roda, Laura Loy, Mariangela Allocca, Laurent Peyrin-Biroulet, Silvio Danese
Current Pharmaceutical Design.2019; 25(1): 7. CrossRef

7,242 View
98 Download
13 Web of Science
11 Crossref

First
Prev
Page of 1
Next
Last

Search